Notch Inhibition in Cancer: Challenges and Opportunities

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The Notch signaling pathway is a critical oncogenic driver in multiple human cancers.
• Current therapeutic strategies for Notch-activated cancers, including gamma-secretase inhibitors and monoclonal antibodies, are limited by severe dose-limiting toxicities.
• There is a significant unmet medical need for effective and safe treatments targeting Notch-driven malignancies.

Purpose of the Study:

• To identify and develop novel small molecule inhibitors targeting the Notch transcription complex.
• To evaluate the efficacy and safety profile of these novel inhibitors, particularly in comparison to existing Notch-targeting agents.
• To address the challenge of on-target toxicities associated with pan-Notch inhibition.

Main Methods:

• Development of novel small molecule inhibitors targeting the Notch transcription complex.
• Preclinical evaluation of these inhibitors for their pan-Notch inhibitory activity.
• Assessment of the toxicity profile, focusing on avoiding dose-limiting toxicities seen with other Notch inhibitors.

Main Results:

• Identification of a novel series of small molecule pan-Notch inhibitors.
• These novel inhibitors demonstrate a favorable safety profile, distinct from the toxicities associated with first- and second-generation Notch inhibitors.
• The lead molecule, CB-103, is currently undergoing Phase-1 dose escalation in cancer patients.

Conclusions:

• Novel small molecules targeting the Notch transcription complex represent a promising therapeutic approach for Notch-activated cancers.
• These inhibitors offer a potential solution to the toxicity challenges that have hindered previous Notch-targeted therapies.
• Cellestia Biotech is advancing these novel molecules, including CB-103, for clinical development and exploring broader applications in cancer and non-cancer indications.